Mechanical Ventilation in Multiple Fracture Ribs

NCT ID: NCT03314701

Last Updated: 2018-07-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-10-25

Study Completion Date

2018-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chest trauma is the most common injury in the emergency trauma and rib fractures is the most common trauma in chest trauma. Severe rib fractures can cause paradoxical respiration and mediastinal swing, which has large effects on respiratory and circulatory system, result in acute respiratory distress syndrome. Mechanical ventilation can significantly improve the hypoxemia of the patients, correct paradoxical respiration, and treat the pulmonary atelectasis

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To compare between Biphasic Intermittent Positive Airway Pressure (BIPAP) ventilation and Airway Pressure Release Ventilation (APRV) mode in patients with multiple fracture ribs as regard:

* Resting Energy Expenditure
* Oxygenation
* Stability of Physiological Status as cardiovascular activity
* cardiac output
* arterial blood gas measurement including \[ blood PH, arterial oxygen tension, arterial carbon dioxide tension, bicarbonate level and base deficit\]
* lung and chest compliance
* Length of intensive care unit stay.
* The ICU mortality rate.
* The development of major complications as nosocomial infection (hospital acquired pneumonia and ventilator associated pneumonia), major atelectasis and pneumothorax.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mechanical Ventilation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Biphasic Intermittent Positive Airway Pressure (BIPAP) group:

Following endotracheal intubation BIPAP mode will be started with:

* Inspiratory positive airway pressure \[IPAP\] at 20 cmH2O
* Expiratory positive airway pressure \[EPAP\] at 5 cmH2O
* PRESSURE SUPPORT is difference between these two pressures \[IPAP\]- \[EPAP\]
* Mandatory pressure will be delivered at rate of 10-12/min. To produce an end tidal carbon dioxide partial pressure in the range of 35-40 mmHg hypercapnia will not be allowed

Group Type ACTIVE_COMPARATOR

Biphasic Intermittent Positive Airway Pressure (BIPAP)

Intervention Type DEVICE

Following endotracheal intubation BIPAP mode will be started with:

* Inspiratory positive airway pressure \[IPAP\] at 20 cmH2O
* Expiratory positive airway pressure \[EPAP\] at 5 cmH2O
* PRESSURE SUPPORT is difference between these two pressures \[IPAP\]- \[EPAP\]
* Mandatory pressure will be delivered at rate of 10-12/min. To produce an end tidal carbon dioxide partial pressure in the range of 35-40 mmHg hypercapnia will not be allowed

Group 2

Airway Pressure Release Ventilation (APRV) group:

* high airway pressure (Phigh) will be set at 20 cmH2O
* low airway pressure ( Plow) will be set at 5 cmH2O
* the release phase setting will be adjusted to terminate the peak expiratory flow rate to ≥ 50%; release frequency of 10-12 cycles/min
* T high at 4.5-6 seconds
* T low at 0.5 to 0.8 second

Group Type ACTIVE_COMPARATOR

Airway Pressure Release Ventilation (APRV)

Intervention Type DEVICE

* high airway pressure (Phigh) will be set at 20 cmH2O
* low airway pressure ( Plow) will be set at 5 cmH2O
* the release phase setting will be adjusted to terminate the peak expiratory flow rate to ≥ 50%; release frequency of 10-12 cycles/min
* T high at 4.5-6 seconds
* T low at 0.5 to 0.8 second

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biphasic Intermittent Positive Airway Pressure (BIPAP)

Following endotracheal intubation BIPAP mode will be started with:

* Inspiratory positive airway pressure \[IPAP\] at 20 cmH2O
* Expiratory positive airway pressure \[EPAP\] at 5 cmH2O
* PRESSURE SUPPORT is difference between these two pressures \[IPAP\]- \[EPAP\]
* Mandatory pressure will be delivered at rate of 10-12/min. To produce an end tidal carbon dioxide partial pressure in the range of 35-40 mmHg hypercapnia will not be allowed

Intervention Type DEVICE

Airway Pressure Release Ventilation (APRV)

* high airway pressure (Phigh) will be set at 20 cmH2O
* low airway pressure ( Plow) will be set at 5 cmH2O
* the release phase setting will be adjusted to terminate the peak expiratory flow rate to ≥ 50%; release frequency of 10-12 cycles/min
* T high at 4.5-6 seconds
* T low at 0.5 to 0.8 second

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

• Isolated chest trauma patient with Multiple fracture ribs patients \[ \>3 ribs\] who will be admitted to the surgical ICU for ventilatory support and will be expected to continue for 2 days or longer

Exclusion Criteria

* Age \< 18 years old.
* Pregnant patient.
* Patient who will require fraction of inspired oxygen more than 0.6.
* Air leak from the chest tube.
* Patient with body temperature \> 39 Celsius.
* Acute hepatitis or severe liver disease (Child-Pugh class C).
* Left ventricular ejection fraction less than 30%.
* Heart rate less than 50 beats/min.
* Second or third-degree heart block.
* Systolic pressure \< 90 mmHg despite of infusion of 2 vasopressors.
* Patients with known endocrine dysfunction.
* Patient with hypothermia
* Patient on Positive end expiratory pressure more than 14 cmH2o
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assiut University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sayed Kaoud Abd-Elshafy

Associate Professor of Anesthesiology and Critical Care

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Faculty of Medicine

Asyut, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

mohamed abdelatef, MD

Role: primary

0020882413201

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRB0000879659

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.